FDA Will Present Brilinta Panel With Alternative Explanation For Negative U.S. Data

FDA reviewers discredit AstraZeneca's suggestion that higher doses of aspirin explain ticagrelor's discordant results for U.S. versus overall trial participants - but also offer an alternative reason for the findings.